Quick Answer
LISATA THERAPEUTICS, INC. reported Net Income Loss of -$16.59 million for the year ending 2025.
- LISATA THERAPEUTICS, INC. showed an increase of +17.0% in Net Income Loss from 2024 to 2025.
- This data is from LISATA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2010 to 2025), LISATA THERAPEUTICS, INC.'s Net Income Loss has grown by 28.8%.
- Historical annual values: Fiscal year 2025: -$16.59 million | Fiscal year 2024: -$19.99 million | Fiscal year 2023: -$20.84 million | Fiscal year 2022: -$54.23 million | Fiscal year 2021: -$27.47 million | Fiscal year 2020: -$8.15 million | Fiscal year 2019: -$19.36 million | Fiscal year 2018: -$16.17 million | Fiscal year 2017: $22.98 million | Fiscal year 2016: -$32.66 million | Fiscal year 2014: -$54.87 million | Fiscal year 2013: -$38.98 million | Fiscal year 2012: -$53.77 million | Fiscal year 2011: -$47.13 million | Fiscal year 2010: -$23.31 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: